Kidney & blood pressure research最新文献

{"title":"Hydronephrosis-Associated Renal Fibrosis: Clinical Validation of Spp1 as a Biomarker and Therapeutic Target.","authors":"Xiao Wang, Jie-Hao Zhou, Guang Chen, Ji-Dong Chen, Hui Li, Wei-Min Shan, Wei-Xiao Li","doi":"10.1159/000546465","DOIUrl":"10.1159/000546465","url":null,"abstract":"<p><strong>Background: </strong>Renal fibrosis is a key driver of chronic kidney disease, often leading to end-stage renal disease (ESRD). Secreted phosphoprotein 1 (Spp1) is implicated in fibrotic processes, but its specific role in renal fibrosis, particularly associated with hydronephrosis, remains underexplored. This study investigates Spp1's involvement using transcriptomic analysis, machine learning, and clinical data integration.</p><p><strong>Methods: </strong>Renal tissues from sham-operated mice with unilateral ureteral obstruction for 7 days were analyzed via transcriptome sequencing to identify differentially expressed genes (DEGs). Hub genes were identified through Weighted Gene Co-Expression Network Analysis and pathway enrichment. LASSO regression pinpointed potential biomarkers, with Spp1 validated in mouse and human samples through RT-PCR and immunohistochemistry. Clinical correlations were drawn from hydronephrosis patient data.</p><p><strong>Results: </strong>Transcriptomic analysis revealed 5,219 DEGs, highlighting key pathways including IL-17, TNF, and PI3K/AKT. Spp1 emerged as a significant biomarker, strongly associated with tubular injury and fibrosis markers such as neutrophil gelatinase-associated lipocalin. Logistic regression and receiver operating characteristic (ROC) analysis confirmed Spp1 and urinary transferrin (U-TRF) as predictors of severe hydronephrosis, with high diagnostic accuracy (area under the ROC curve: 0.898 for Spp1; 0.938 for U-TRF).</p><p><strong>Conclusions: </strong>Spp1 is a critical mediator in renal fibrosis and a promising biomarker for assessing hydronephrosis severity. Its diagnostic value, particularly when combined with U-TRF, underscores the need for further research into Spp1-targeted therapies in renal fibrosis.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"460-480"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12234011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nephroprotective Effect of <italic>Mucuna pruriens</italic>, <italic>Moringa oleifera</italic>, <italic>and</italic> Milk Thistle Extracts against Acetaminophen-Induced Acute Kidney Injury in Mice.","authors":"Iman Al Housseini, Hoda Dakdouk, Jamilah Borjac","doi":"10.1159/000547253","DOIUrl":"10.1159/000547253","url":null,"abstract":"<p><strong>Introduction: </strong>Acute kidney injury (AKI) is a rapid and often reversible decline in renal excretory function. Acetaminophen (APAP) overdose causes AKI. APAP nephrotoxicity is mostly due to the overproduction of reactive oxygen species (ROS). As no effective treatment for AKI is available, researchers are looking for natural and safe alternatives using plants. In this study, they aimed to evaluate the nephroprotective effects of Moringa oleifera (Mor), Mucuna pruriens (Muc), or milk thistle (MT) at the biochemical and molecular levels in an APAP-induced AKI mouse model.</p><p><strong>Methods: </strong>AKI was induced in mice with a single intraperitoneal dose of APAP (1,000 mg/kg). The aqueous extracts of the three plants were given orally at 350 mg/kg daily for 21 days pre-AKI induction. Creatinine and BUN levels were measured in serum to assess kidney function. The oxidative stress and inflammatory indicators SOD, CAT, MDA, IL-6, and TNF-α were determined using colorimetric and ELISA kits, respectively. SIRT1 protein levels were determined by Western blot.</p><p><strong>Results: </strong>Pretreatment with the three plant extracts significantly decreased the kidney biomarkers. SOD and CAT activities were enhanced with a decrease in MDA levels. IL-6 and TNF-α were also significantly lowered. A significant increase in SIRT1 expression was observed.</p><p><strong>Conclusion: </strong>Pretreatment with Mor, Muc, and MT has a nephroprotective effect against APAP-induced kidney injury, regulating oxidative stress and inflammatory response.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"523-532"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genome-Based Advances in Modeling Renal Ciliopathies and Enhancing Patient Care.","authors":"Floriana Secondulfo, Francesca Del Vecchio Blanco, Giovanna Capolongo, Giulio Piluso, Vincenzo Nigro, Alessandra F Perna, Giovambattista Capasso, Miriam Zacchia","doi":"10.1159/000547131","DOIUrl":"10.1159/000547131","url":null,"abstract":"<p><strong>Background: </strong>Genetic diseases collectively affect more than 300 million individuals worldwide, posing a significant health burden, as diagnosis is often challenging and therapeutic options are limited. Recent genetic technological advancements are improving the management of many inherited disorders, including genetic kidney disorders (GKDs), the leading cause of early-onset chronic kidney disease (CKD) and the cause of 10-15% of kidney replacement therapy in adults.</p><p><strong>Summary: </strong>GKDs fall into different clinical categories, including cystic and fibro-cystic diseases in the setting of ciliopathies, rare conditions caused by the dysfunction of the primary cilium, typically characterized by multiorgan dysfunction. CKD is a significant cause of morbidity and mortality in these patients and a correct diagnosis is crucial for patient's management.</p><p><strong>Key message: </strong>The present review analyzes whether advances in genomic technologies have provided benefit in the ciliopathy field, in both modeling renal diseases and improving patient's care.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"545-563"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144506067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the Fatty Liver Index, Metabolic Dysfunction-Associated Steatotic Liver Disease, and the Risk of Kidney Stones.","authors":"Fan Zhang, Wenjian Li","doi":"10.1159/000543404","DOIUrl":"10.1159/000543404","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to investigate the potential association between the fatty liver index (FLI), metabolic dysfunction-associated steatotic liver disease (MASLD), and the risk of kidney stones using large-scale population-based data.</p><p><strong>Methods: </strong>This study employed a cross-sectional design, utilizing data from the 2007 to 2018 National Health and Nutrition Examination Survey (NHANES) database. A total of 24,342 participants were enrolled in the study, and fatty liver status was assessed by calculating the FLI. MASLD was diagnosed by FLI in conjunction with cardiometabolic criteria. Data on the history of kidney stones were obtained by self-report. We employed logistic regression models to analyze the association between FLI, MASLD, and kidney stone risk and constructed multivariable adjustment models to control for potential confounders. Furthermore, we used restricted cubic spline curve models to investigate the dose-response relationship between FLI and kidney stone risk and conducted subgroup and interaction analyses.</p><p><strong>Results: </strong>The study's results indicate a strong correlation between increasing FLI quartiles and a notable rise in the prevalence of kidney stones. Specifically, the risk of developing kidney stones was 1.68 times higher among participants in the highest FLI quartile compared to those in the lowest. Furthermore, patients with MASLD exhibited a 1.35-fold increased risk of developing kidney stones compared to those with non-MASLD. Subgroup analyses demonstrated that the correlation between MASLD and kidney stone risk was consistent across multiple subgroups. However, a significant interaction was observed in the subgroups of smoking status, physical activity level, and hypertension (interaction p < 0.05). The restricted cubic spline analysis did not yield a statistically significant nonlinear association between FLI and kidney stone risk. However, the study did identify inflection point values for FLI.</p><p><strong>Conclusion: </strong>This study demonstrated an association between FLI and MASLD and the risk of kidney stones. This suggests that these conditions may be pivotal risk factors for kidney stones. Further investigation is required to elucidate these associations' underlying mechanisms and develop efficacious interventions to reduce the risk of kidney stones. Also, formulating personalized prevention and treatment strategies for different population subgroups is paramount.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"115-130"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Steroidal Mineralocorticoid Receptor Antagonists: A Paradigm Shift in the Management of Diabetic Nephropathy.","authors":"Justine Huart, François Jouret","doi":"10.1159/000545286","DOIUrl":"10.1159/000545286","url":null,"abstract":"<p><strong>Background: </strong>Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease worldwide. The management of DKD relies on controlling glycemia and blood pressure levels, as well as reducing proteinuria. While the traditional renin-angiotensin-aldosterone system inhibitors (RAASi) and the recently approved type 2 Na+/glucose co-transporter inhibitors (SGLT2i) have significantly improved patient outcomes, residual risks remain unaddressed.</p><p><strong>Summary: </strong>This review explores (1) the mechanisms of action of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (ns-MRA), (2) the evidence of finerenone-induced kidney protection in clinical trials, and (3) the comparative advantages over conventional MRAs. The potential synergy between finerenone and SGLT2i is also addressed, alongside research perspectives and practical considerations for implementation in clinical practice.</p><p><strong>Key messages: </strong>Finerenone has emerged as a breakthrough therapy in the management of DKD, demonstrating robust nephro- and cardio-protective effects.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"267-275"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Irisin Levels Are Positively Correlated with Physical Activity Capacity in Hemodialysis Patients.","authors":"Zhengjia Fan, Feng Wu, Peixin Wang, Leiyun Wu, Jialing Zhang, Wen Li, Qi Pang, Aihua Zhang","doi":"10.1159/000543214","DOIUrl":"10.1159/000543214","url":null,"abstract":"<p><strong>Introduction: </strong>Regular physical activity is beneficial for health but is often reduced in patients receiving maintenance hemodialysis treatment. Irisin is a muscle-secreted hormone that reportedly improves metabolism and slows down the progression of some chronic diseases. In this study, we aimed to investigate the relationship between physical activity capacity and serum irisin levels in hemodialysis patients.</p><p><strong>Methods: </strong>Our study included 252 patients undergoing hemodialysis at Xuanwu Hospital Capital Medical University. Enzyme-linked immunosorbent assay was used to measure blood irisin levels. Body composition was analyzed by bioelectrical impedance analysis. The International Physical Activity Questionnaire (IPAQ) was used to score physical activity ability.</p><p><strong>Results: </strong>Bivariate correlation analysis showed a positive correlation between IPAQ scores and ln irisin (the natural logarithm of irisin; r = 0.326, p < 0.001). Independent determinants of IPAQ scores were ln irisin, age, fasting glucose, and carbon dioxide combining power.</p><p><strong>Conclusion: </strong>Our findings provide the first clinical evidence that serum irisin levels are positively correlated with physical activity capacity in hemodialysis patients.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"105-114"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Values of Serum Platelet-Activating Factor in Hypertensive Disorders Complicating Pregnancy.","authors":"Shasha Liu, Qianyu Lan, Weiling Li, Jiefang Zhang, Liman Fu, Yanlei Xu, Yuan Li","doi":"10.1159/000543242","DOIUrl":"10.1159/000543242","url":null,"abstract":"<p><strong>Introduction: </strong>Serum platelet-activating factor (PAF) was proven to be associated with gestational hypertension. However, the predictive value of serum PAF at early pregnancy for the occurrence and outcomes of hypertensive disorders complicating pregnancy (HDCP) remained unclear.</p><p><strong>Methods: </strong>The demographic and clinical characteristics of patients were compared among the different subgroups. The serum PAF level was determined using an enzyme-linked immunosorbent assay. The predictive value of serum PAF for the occurrence and outcomes of HDCP was evaluated using receiver operating characteristic curve analysis. The correlation of serum PAF with blood pressure was assessed using Spearman analysis.</p><p><strong>Results: </strong>Both systolic blood pressure and diastolic blood pressure were significantly higher in HDCP patients, as well as the serum levels of TNF-α and IL-1β at diagnosis/enrollment, while serum levels of IL-10 showed the opposite trend. Serum PAF levels were significantly higher in patients with HDCP compared to normal pregnant women. Furthermore, serum PAF levels were higher in HDCP patients with mild preeclampsia compared to those with gestational hypertension and even more elevated in HDCP patients with severe preeclampsia at the early pregnancy stage and at diagnosis. In HDCP patients, increased serum PAF levels at early pregnancy and at diagnosis were associated with poor outcomes. Additionally, serum PAF levels could predict the occurrence of HDCP and poor outcomes.</p><p><strong>Conclusion: </strong>Serum PAF from HDCP patients at both the early pregnancy and diagnosis stages could effectively predict the occurrence and outcome of HDCP.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"151-160"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles of Serum NLRP3 Inflammasome and Associated Cytokines in Gout-Induced Kidney Injury.","authors":"Xiaoqing Xu, Juanjuan Zhang, Yanqun Wu","doi":"10.1159/000545492","DOIUrl":"10.1159/000545492","url":null,"abstract":"<p><strong>Introduction: </strong>Gout, characterized by hyperuricemia and urate crystal deposition, is associated with systemic inflammatory complications, including kidney injury. This study aimed to investigate the role of serum nucleotide-binding oligomerization domain-like receptor 3 (NLRP3) inflammasome and associated cytokines (IL-1β and IL-18) in gout-related kidney injury (GRI).</p><p><strong>Methods: </strong>A total of 279 gout patients (96 with renal injury and 183 without renal injury) and 100 healthy controls were included. Serum NLRP3, IL-1β, and IL-18 were measured and compared using an enzyme-linked immunosorbent assay. Receiver operating characteristic (ROC) analysis was carried out to evaluate the diagnostic values of individual or combinational biomarkers. Spearman's correlation analysis was employed to analyze correlations between NLRP3, IL-1β, and IL-18 and renal function indicators or serum uric acid.</p><p><strong>Results: </strong>Serum levels of NLRP3, IL-1β, and IL-18 were significantly higher in gout patients compared to healthy controls (p < 0.001, gout group with kidney injury [GKI]: n = 96, gout group without kidney injury [GNKI]: n = 183, controls: n = 100), with elevated levels observed in GKI patients compared to GNKI (p < 0.001). Correlations between these markers were confirmed among all gout patients (n = 279), including serum NLRP3 with IL-1β (r = 0.34, p < 0.001) and NLRP3 with IL-18 (r = 0.47, p < 0.001). ROC analysis revealed that the combined model of NLRP3, IL-1β, and IL-18 showed improved diagnostic accuracy for GRI, with an AUC of 0.85 (95% CI: 0.81-0.89, p < 0.001). In GKI patients (n = 96), serum NLRP3, IL-1β, and IL-18 were inversely correlated with eGFR (NLRP3: r = -0.43, p < 0.01). Additionally, serum IL-18 positively correlated with serum uric acid levels (r = 0.27, p = 0.009).</p><p><strong>Conclusion: </strong>These findings highlight the potential of serum NLRP3, IL-1β, and IL-18 as diagnostic markers and therapeutic targets in GRI, providing insights into early intervention and improved clinical outcomes in gout patients with renal complications.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"341-350"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"End-Stage Chronic Kidney Disease Affects Serum Nostrin Turnover.","authors":"Vivien Latuske, Stefan Erfurt, Daniel Patschan, Meike Hoffmeister","doi":"10.1159/000545521","DOIUrl":"10.1159/000545521","url":null,"abstract":"<p><strong>Introduction: </strong>Serum Nostrin was recently identified as novel predictor of important clinical outcomes in acute kidney injury (AKI) and has also emerged as a predictor of recovery of kidney function (ROKF) in AKI patients. ROKF is a critical factor for the transition of AKI into chronic kidney disease (CKD). Therefore the aim of the present study was to evaluate serum Nostrin levels in CKD patients.</p><p><strong>Methods: </strong>Blood samples were collected from CKD patients before and after dialysis, and serum Nostrin levels were determined using ELISAs.</p><p><strong>Results: </strong>Serum Nostrin levels were previously shown to be significantly increased in AKI patients in comparison with healthy controls. In CKD patients, the levels of serum Nostrin were further increased without significant differences of Nostrin concentrations before and after dialysis.</p><p><strong>Conclusion: </strong>The further elevation of serum Nostrin concentrations in CKD in comparison with AKI indicates a significant impairment of Nostrin turnover and supports the possible suitability of Nostrin as potential diagnostic value in both AKI and CKD.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"321-324"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perirenal Fat and Chronic Kidney Disease: A Systematic Review and Meta-Analysis.","authors":"Pengfei Kang, Boju Sun, Jing Hao, Conghui Wang, Xiangmei Chen","doi":"10.1159/000543989","DOIUrl":"10.1159/000543989","url":null,"abstract":"<p><strong>Introduction: </strong>Although previous studies have investigated the impact of perirenal fat on chronic kidney disease (CKD), there are yet no systematic reviews and meta-analyses to investigate the association between perirenal fat and CKD.</p><p><strong>Methods: </strong>We searched six English electronic databases including PubMed, Scopus, Web of Science, Ovid, Embase, and the Cochrane Library to select clinical studies that reported the relationship between perirenal fat and CKD, and the search period ranged from the establishment of the database to September 10, 2024. Two researchers independently screened the studies and ultimately compared the literature. Stata (version 16 SE; College Station, TX, USA) software was used for statistical analysis.</p><p><strong>Results: </strong>A total of eight articles that included 2,576 patients were included in this meta-analysis. The results showed a significant association between perirenal fat and CKD (95% CI: 0.48-0.65, p = 0.00), and no heterogeneity was detected between these two groups (I2 = 31.06%, p = 0.18). Subgroup analysis revealed that whether it is diabetic nephropathy, nephropathy caused by abnormal cardiac function, or primary CKD, perirenal fat is closely related to them.</p><p><strong>Conclusion: </strong>The results of this systematic review and meta-analysis showed that perirenal fat thickness is closely related to CKD. Clinicians should pay attention to relevant indicators when diagnosing and treating patients with CKD.</p>","PeriodicalId":17813,"journal":{"name":"Kidney & blood pressure research","volume":" ","pages":"240-248"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}